Zhu Sha (Cinnabar)

Chinese Herb Actions

Chinese Herb Dosage

• Is Zhu Sha (Cinnabar) safe to use, and what dosage limits appear in regulatory texts?

  Zhu Sha is not recommended for use. Where it has historically been permitted in a regulated pharmacopoeia, the allowable ceiling has been set very low and has been repeatedly tightened over time — a regulatory trend documented in the toxicology literature, not usage guidance. No administration, preparation, or dosing information is given here.

  • Documented regulatory tightening — the Chinese Pharmacopoeia’s allowable daily amount of cinnabar in the medicines that contain it was cut by as much as 65%, from 0.3–1.5 g in the 1977 edition to 0.1–0.5 g in the 2005 edition, reflecting escalating safety concern over the intervening decades.
  • Still far above Western safety limits — even after that reduction, researchers note the resulting mercury content in cinnabar-containing preparations remains orders of magnitude above allowable mercury limits in Western countries.

  Source: PMID 18445765 / PMC 2755212 (Liu et al., Experimental Biology and Medicine, 2008), reporting Chinese Pharmacopoeia dose-ceiling history. Regulatory/historical reference only — not usage guidance.

Chinese Herb Contraindications & Cautions

• Are there cautions or contraindications for Zhu Sha (Cinnabar)?

  Zhu Sha is not recommended for use. As a mercury-sulfide mineral, it carries safety concerns documented consistently across TCM reference sources and the toxicology literature, and its use (where it occurs at all) is described as professional-supervised and strictly time-limited — never a general-purpose or self-administered substance.

  • Pregnancy and breastfeeding — mercury is documented to cross the placental barrier; cinnabar-containing preparations are described as contraindicated in pregnancy and lactation across TCM safety references.
  • Hepatic and renal impairment — because absorbed mercury accumulates in and can damage the liver and kidneys, pre-existing hepatic or renal dysfunction is documented as a contraindication.
  • Children and older adults — TCM safety references flag heightened susceptibility to mercury toxicity in children specifically, with extra caution also noted for elderly patients.
  • Not for repeated or prolonged exposure — because mercury accumulates in body tissue with repeated exposure, sources describe cinnabar-containing products as unsuitable for extended or repeated use.

  Source: cross-checked TCM materia medica safety references; toxicology literature (see Toxicity, below). Neutral safety reference; not usage instructions.

Chinese Herb Toxicity & Overdose

• Zhu Sha is a documented mercury-toxicity hazard. Its principal component, mercuric sulfide (HgS), is chemically more inert and less readily absorbed from the gastrointestinal tract than soluble mercury salts — oral absorption is reported at well under 0.2%, versus roughly 12.5% for mercuric chloride — but the fraction that is absorbed still accumulates in tissue and produces well-documented organ toxicity, and this relative insolubility does not make the substance safe.

  Documented toxicity pattern:

  • Hepatotoxicity and nephrotoxicity — absorbed mercury accumulates primarily in the kidneys, with animal studies documenting hepatic and renal tissue damage, including proximal-tubule injury, after prolonged or higher-dose exposure.
  • Neurotoxicity — animal studies report neurobehavioral deficits, altered brain-tissue enzyme activity (including Na⁺/K⁺-ATPase), and effects on offspring following low-dose cinnabar exposure, with mercury accumulation correlating to the severity of neurobehavioral change; a substantially higher dose than methylmercury is needed to reach comparable neurotoxic effect.
  • Ototoxicity — guinea-pig research reports a neurotoxic effect of cinnabar and mercuric sulfide on the vestibulo-ocular reflex system.
  • Chemical fate in the body — cinnabar (HgS) is documented not to be converted into methylmercury by human intestinal bacteria; it is instead transformed toward mercuric polysulfides, a toxicologically distinct pathway from organic-mercury (e.g., fish methylmercury) exposure.
  • Inhalation hazard when heated — the toxicology literature separately documents that heating cinnabar releases mercury vapor, an inhalation-toxicity hazard distinct from oral exposure; this is noted here as a hazard fact, not a preparation instruction.

  Sources: PMID 18445765 / PMC 2755212 (oral absorption comparison, Liu et al. 2008); PMID 22888198 (neurotoxicological effects in offspring mice); PMID 11370760 (active avoidance, Na⁺/K⁺-ATPase, rats); PMID 12011485 (vestibulo-ocular neurotoxicity, guinea pigs); PMID 21382464 (cinnabar not converted to methylmercury by intestinal bacteria); DOI 10.3389/fphar.2022.807807 / PMC 8924441 (mercury-vapor inhalation hazard, mechanism overview). Reference safety information, not a description of use.

• This herb is considered toxic.
  (while some Chinese herbs are toxic, it must be noted that many come prepared, or are combined, to mitigate their toxicity)

Herb-Drug Interactions

• Zhu Sha is documented to react dangerously with iodide- and bromide-containing medications. TCM pharmacology references describe mercury from cinnabar combining with iodide or bromide ions (for example, potassium-iodide-based expectorants or bromide sedatives) to form corrosive mercuric iodide/bromide salts, which have been associated with drug-induced enteritis and bloody diarrhea; concurrent exposure to iodide/bromide medications alongside cinnabar-containing preparations is therefore flagged as hazardous in these references. No well-controlled clinical drug-interaction trials exist for Zhu Sha — this is reference/mechanistic information, not a demonstrated clinical interaction. Because mercury is independently documented as hepatotoxic and nephrotoxic (see Toxicity), concurrent exposure to other hepatotoxic or nephrotoxic substances is also a reasonable theoretical concern flagged here for reference, not a demonstrated interaction. (Flagged for practitioner/toxicologist confirmation.)

Western / Biomedical Research

Chinese Herb Clinical Studies & Research

Provided as research context — a summary of published biomedical study, not a therapeutic or medical claim.

• Is there modern research on Zhu Sha / Cinnabar (Cinnabaris, HgS)?

  Yes — a substantial body of toxicology and pharmacokinetic research exists, and it is overwhelmingly focused on documenting mercury-related hazard rather than establishing therapeutic benefit or safety. No controlled human clinical-efficacy trials of cinnabar itself were identified; the literature is toxicological, mechanistic, and regulatory in character.

  • Comparative toxicology — a 2008 study concluded cinnabar is chemically less readily absorbed and less acutely toxic than many other mercury forms when taken orally, while explicitly stating that “the rationale for its inclusion in traditional Chinese medicines remains to be fully justified.”
  • Herbo-metallic safety review — a 2012 toxicological review of mercury-based traditional herbo-metallic preparations (cinnabar and related substances) found that the mechanism of action has not been conclusively established, and called for long-term safety studies, quality control, and pharmacovigilance.
  • Comprehensive TCM mercury review — a 2022 review of mercury-containing preparations in traditional Chinese medicine documents cinnabar’s historical use, confirms organ-specific toxicity (hepatic, renal, neurological), and describes a regulatory trend of narrowing the permitted use of mineral drugs, including restriction of some cinnabar-containing patent medicines and removal of cinnabar from products intended for export markets.
  • Formula-level toxicology — metabolomic research on Zhusha Anshen Wan (a classical cinnabar-containing formula) reports measurable hepatic, renal, and intestinal metabolic effects attributable to the cinnabar component, studied specifically to characterize the toxicity risk of that formula.
  • Neurotoxicity and biotransformation research — separate animal studies document neurobehavioral, enzymatic, and vestibular effects of cinnabar exposure, and confirm that cinnabar is not converted to methylmercury by human intestinal bacteria (see Toxicity for details and citations).

  Overall: modern research on Zhu Sha is toxicology- and safety-focused, consistently documents mercury-related organ toxicity, and reflects an active, ongoing regulatory trend toward restricting its use; it does not establish cinnabar as safe for use.

  Sources: PMID 18445765 / PMC 2755212 (Liu et al., Experimental Biology and Medicine, 2008); PMID 22441626 (Kamath et al., Archives of Toxicology, 2012); DOI 10.3389/fphar.2022.807807 / PMC 8924441 (Zhao, Li & Wang, Frontiers in Pharmacology, 2022); PMC 10871036 / DOI 10.3389/fphar.2024.1353325 (Zhusha Anshen Wan metabolomics, Frontiers in Pharmacology, 2024); PMID 22888198; PMID 11370760; PMID 12011485; PMID 21382464. Research context, not a therapeutic claim.

Chinese Herb Notes

• How does Zhu Sha differ from other Spirit-calming minerals in this category, and where does it appear historically?

  Zhu Sha is the only mercury-based, toxic mineral in the Sacred Lotus “anchor, settle, and calm the Spirit” category — the other minerals classed alongside it (Long Gu, Long Chi, Mu Li, Zhen Zhu, Zhen Zhu Mu, Ci Shi, Dai Zhe Shi) are calcium- or iron-based substances without a comparable mercury-toxicity profile. This distinction is the main practical difference within the category.

  • Historical formula appearances — this site’s own record records Zhu Sha as a historically listed ingredient in ten classical formulas, including Zhu Sha An Shen Wan (“Cinnabar Pill to Calm the Spirit”), An Gong Niu Huang Wan, Zi Xue Dan, Zhi Bao Dan, Ci Zhu Wan, Sheng Tie Luo Yin, Qi Li San, Hui Chun Dan, Su He Xiang Wan, and Ding Xian Wan. These are documented as historical/classical formula composition, not a current usage recommendation.
  • Modern reformulation trend — a 2022 pharmacology review of mercury-containing traditional Chinese medicines describes an ongoing regulatory “narrowing” of mineral-drug use, with several cinnabar-containing patent medicines restricted and mineral ingredients including cinnabar and realgar removed from products intended to meet export-market requirements.

  Source: this site’s own record (herb category and formula records); DOI 10.3389/fphar.2022.807807 / PMC 8924441 (Zhao, Li & Wang, Frontiers in Pharmacology, 2022, regulatory/reformulation trend). Historical/comparative reference only.

This herb is toxic or restricted in the United States